Slide 1: Fourth Quarter and Full Year 2024 Financial Results
March 27, 2025 Fourth Quarter and Full Year 2024 Financial Results
Slide 2: Welcome and Participants
Welcome and Participants Dr. Jeffrey Graves President & Chief Executive Officer Jeffrey Creech Executive Vice President & Chief Financial Officer Mick McCloskey Vice President, Treasury & Investor Relations To participate via phone, please dial: 1-201-689-8345 2
Slide 3: Forward Looking Statements
Forward Looking Statements Certain statements made in this presentation that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncert
Slide 4: Dr. Jeffrey Graves
Dr. Jeffrey Graves President & Chief Executive Officer 4
Slide 5: 2024 Highlights
2024 Highlights Delivered FY’24 Revenues within Expectations • Challenging top-line environment across the industry driven by uncertain macro conditions • Q4 revenues include ~$9mm unfavorable change in accounting estimate impact not previously considered in original guidance • Core operations perfo
Slide 6: Transforming Manufacturing for a Better Future
Transforming Manufacturing for a Better Future Industrial Solutions Healthcare Solutions Transportation & Dental Craniomaxillofacial Motorsports Aerospace & Defense Orthopedics Virtual Surgical Planning Oil, Gas and Energy AI Infrastructure
Slide 7: Dental Growth Strategy ~$1 Billion US Market Opportunity
Dental Growth Strategy Straighten Protect Repair Replace Indirect & direct printed Nightguards; near-term Multi-material monolithic aligners; established opportunity w/ Crowns & bridges jetted dentures; already market leader NextDent 300 received FDA approval 2029E US Addressable Market* ~$125mm ~$6
Slide 8: Historic Year of Innovation and more to come in 2025
Historic Year of Innovation and more to come in 2025 Offering the widest range of technology in the industry MJP 300W DMP 350 Triple EXT 800 Titan Pellet PSLA 270 Disciplined approach to R&D brings dozens of new products to market in FY’24, now entering commercialization phase Figure 4 135 SLS 380 S
Slide 9: Cost Reduction & Profitability Improvement Initiatives
Cost Reduction & Profitability Improvement Initiatives New program targeted to deliver +$50mm annualized savings over next 6 quarters •Raw material & •Indirect supplier sourcing •Insourced procurement & Manufacturing & •Factory vendor spend Prior Restructuring Supply Chain Gross Margin utilization,
Slide 10: 2025 Outlook
2025 Outlook Based on current macroeconomic conditions, we expect the following for FY’25: ✓ Revenues (normalized for divestiture) ranging from essentially flat-to- modest-growth ✓ Growth in gross margins driven by efficiency plans, despite divestiture of accretive software business ✓ YoY OpEx impro
Slide 11: Jeffrey Creech
Jeffrey Creech Chief Financial Officer 11
Slide 12: Q4 Revenue Summary
Q4 Revenue Summary ($ in millions) Industrial Solutions Healthcare Solutions Consolidated $71 $51 $115 $111 $64 $40 Q4’23 Q4’24 Q4’23 Q4’24 Q4’23 Q4’24 • ISG increased 11% YoY, driven by • HSG declined ~21% YoY primarily • YoY revenue decreased ~3% as strength in nearly every vertical, with due to ~
Slide 13: Full Year Revenue Summary
Full Year Revenue Summary ($ in millions) Industrial Solutions Healthcare Solutions Consolidated $275 $250 $213 $488 $440 $190 FY’23 FY’24 FY’23 FY’24 FY’23 FY’24 • ISG revenues declined ~9% YoY • HSG declined ~11% YoY driven by • YoY revenue declined ~10% primarily largely impacted by macro-related
Slide 14: Gross Profit Margin
Gross Profit Margin (Non-GAAP) Fourth Quarter Compare Full Year Compare 39.8% 40.6% 38.7% 36.3% 37.4% 31.3% • Q4 gross margin primarily driven by ~$9mm change in accounting estimate • FY gross margin primarily driven by change in accounting estimate, increase in inventory reserves and lower volumes
Slide 15: Operating Expense
Operating Expense (Non-GAAP) ($ in millions) • Consistent sequential improvement, in addition to year-over-year improvement, primarily driven by previously announced cost reduction programs $65.4 $66.3 $64.2 $61.4 $58.4 • Based on additional actions, OpEx continues to represent a significant opportu
Slide 16: Earnings (Non-GAAP)
Earnings (Non-GAAP) ($ in millions, except per share amounts) FY’23 FY’24 Q4 Drivers Adj. EBITDA ($26.3) ($66.4) • Primarily driven by revenue and gross margin in Non-GAAP connection with change in accounting estimate Diluted loss per ($0.28) ($0.62) • Partially offset by reduction in OpEx share Q4’
Slide 17: Balance Sheet
Balance Sheet ($ in millions) • Opportunistically repurchased +50% of outstanding 2026 debt at a discount in FY’23 & FY’24 • Cash used in operations of ~$45mm, improving ~$36mm YoY; significant working capital focus driven by inventory reductions • Post Geomagic transaction (targeted early Q2), expe
Slide 18: 2025 Outlook
2025 Outlook Full Year 2025 Guidance Additional Commentary • Current macroeconomic and uncertain geopolitical $420 million – $435 million environment to continue impacting top-line – Revenue Representing flat to modest growth expecting flat-to-modest growth excluding Geomagic adjusted for divestitur
Slide 19: Q&A Session
Q&A Session 1-201-689-8345 19
Slide 20: Thank You
Thank You Find out more at: www.3dsystems.com 20
Slide 21: Appendix
Appendix ©2025 3D Systems, Inc. | All Rights Reserved.
Slide 22: Presentation of Information
Presentation of Information 3D Systems reports its financial results in accordance with GAAP. Management also reviews and reports certain Non-GAAP measures, including: Non-GAAP revenue excluding divestitures and on a constant currency basis (sometimes referred to as excluding divestitures and FX eff
Slide 23: Reconciliation: Gross Profit and Gross Profit Margin
Appendix 3D Systems Corporation Unaudited Reconciliations of GAAP to Non-GAAP Measures Gross Profit and Gross Profit Margin Three Months Ended December 31, (in millions) 2024 2023 Gross Profit Cae Gross Profit Ga GAAP $ 34.4 31.0% $ 44.0 38.3% Amortization expense included in Cost of sales 02 o4 Sev
Slide 24: Reconciliation: Non-GAAP Operating Expense
Appendix 3D Systems Corporation Unaudited Reconciliations of GAAP to Non-GAAP Measures Non-GAAP Operating Expense” Three Months Ended December 31, Year Ended December 31, (in millions) 2024 2023 2024 2023 Operating expense $ 648 $ 3713, § 4416 $ 602.4 Amortization expense (0.8) (2.0) (13.3) (11.6) S
Slide 25: Reconciliation: Net Loss to Adjusted EBITDA
Appendix 3D Systems Corporation Unaudited Reconciliations of GAAP to Non-GAAP Measures Net Loss to Adjusted EBITDA ® Three Months Ended December 31, Year Ended December 31, (in millions) 2024 2023 2024 2023 Net loss attributable to 3D Systems Corporation $ G37) $ 292.7) $ (255.6) $ (362.7) Interest
Slide 26: Reconciliation: Diluted Loss per Share
Appendix 3D Systems Corporation Unaudited Reconciliations of GAAP to Non-GAAP Measures Diluted Loss per Share ® Three Months Ended December 31, Year Ended December 31, (in dollars) 2024 2023 2024 2023 Diluted loss per share $ (25) $ Q25 $ (194) $ (2.79) Amortization expense 0.01 0.02 O11 0.09 Stock-